Guardian Pharmacy Services, Inc. (GRDN) Guidance & Earnings Results

On 2026-08-06 Guardian Pharmacy Services, Inc. raised guidance: "Revenue guidance raised to $1.43-$1.45B from $1.40-$1.42B; Adjusted EBITDA raised to $129-$131M from…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

GRDNGuardian Pharmacy Services, Inc.Follow GRDN — free

Medical Care Facilities · Healthcare

—

Price chart with a free account

Market cap: 2.5B
P/E TTM: 38.7
Dividend yield: —
52-week: —
Next earnings: 17 Nov, in 24 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Aug 26	Raised	Revenue guidance raised to $1.43-$1.45B from $1.40-$1.42B; Adjusted EBITDA raised to $129-$131M from $122-$127M · full year
6 May 26	Raised	Adjusted EBITDA guidance raised to $123-127M from $120-124M · full year
11 Mar 26	Raised	FY2026 Adjusted EBITDA guidance raised from $115-118M to $120-124M; revenue guidance unchanged at $1.40-1.42B · full year
10 Nov 25	Raised	FY2025 revenue $1.43B-$1.45B, Adjusted EBITDA $104M-$106M · full year
11 Aug 25	Raised	FY25 revenue raised to $1.39-1.41B from $1.33-1.35B; FY25 adjusted EBITDA raised to $100-102M from $97-101M · full year

Guardian Pharmacy Services, Inc. — questions

What guidance did Guardian Pharmacy Services, Inc. give?: On 2026-08-06: "Revenue guidance raised to $1.43-$1.45B from $1.40-$1.42B; Adjusted EBITDA raised to $129-$131M from $122-$127M"
When does Guardian Pharmacy Services, Inc. report earnings?: Guardian Pharmacy Services, Inc.'s next earnings report is expected on 2026-11-17.

Every figure on this page comes from Guardian Pharmacy Services, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.